Local Treatment for Perineal and Perianal Rhabdomyosarcoma: Clinical Practice Guidelines and Consensus Statement From the Children's Oncology Group, European Pediatric Soft Tissue Sarcoma Study Group, the Cooperative Weichteilsarkom Studiengruppe, and the International Soft Tissue Sarcoma Consortium
In brief
Experts set local-treatment guidance for rare perineal childhood cancer
A consensus guideline brings together recommendations from three pediatric oncology groups for treating rhabdomyosarcoma around the perineum and anus, a rare cancer with reported 5-year survival of 39% to 52%. It covers surgery, lymph node staging and radiation options, but is based on literature review and expert opinion rather than comparative trials, so the best approach remains uncertain.
- Journal
- Pediatric blood & cancer (Q1)
- Published
- 20 November 2026
- Study design
- Practice guideline / consensus
- Evidence level
- Level 1, High (CEBM 1c)
- Authors
- Guido Seitz, Illya Martynov, Joerg Fuchs, Beate Timmermann, Christine Hansel, Daniel J Indelicato, et al.
- PMID
- 43062201
- DOI
- 10.1002/1545-5017.70807
Why clinicians should know about it
- Picked for Radiation Oncology (top studies of the week, 22 November 2026): Multidisciplinary local-treatment guidelines include radiotherapy, protons, and brachytherapy
- Picked for Pediatric Surgery (top studies of the week, 22 November 2026): Consensus guideline addresses pediatric perineal tumor surgery
Abstract
Local control of rhabdomyosarcoma in the perianal and perineal region (PRMS) is challenging due to the unfavorable tumor location, the often advanced stage of disease, the prevalence of alveolar histology with PAX3/FOXO1 fusion, and frequent regional lymph node (LN) involvement at presentation. Distant metastases are present at diagnosis in up to 49% of patients. Given the high risk of recurrence, the prognosis of patients with PRMS treated with multimodal treatment is poor, with a reported 5-year overall survival (OS) rate of 39%-52%. Due to the rarity of PRMS along with variations in treatment protocols over time and across different cooperative groups, we have developed consensus local treatment guidelines. This guideline is based on a comprehensive literature review and expert opinion and is endorsed by the International Soft-Tissue Sarcoma Consortium (INSTRuCT). It integrates insights from three leading pediatric oncology cooperative groups: the Cooperative Weichteilsarkom Studiengruppe (CWS; since December 2024 part of European pediatric Soft-tissue sarcoma Study Group [EpSSG]), Children's Oncology Group (COG), and EpSSG. This document addresses surgical therapy options, including biopsy, nodal staging, and various resection modalities, as well as options for radiotherapy, such as intensity-modulated radiation therapy, proton beam therapy, and brachytherapy.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.